The efficacy of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in the Gambia: 2013 follow up study

Medical Research Council Unit0 个研究点目标入组 120 人开始时间: 2013年10月21日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•1. Age above 1 year to 12 years
•2. Mono-infection with P. falciparum determined by microscopy
•3. Parasite density between 1000 and 100,000/µl asexual forms
•4. Axillary temperature ¿ 37.5 °C and/or history of fever during the past 24 hours
•5. Ability to swallow oral medication
•6. Ability and willingness to comply with the study protocol; resident in the study area for the duration of the study and willing to come for all scheduled study visits
•7. Informed consent from the caregiver (parent or guardian).

•1.Danger signs or signs of severe falciparum malaria based on standard WHO
•2.Mixed infection with Plasmodium species other than falciparum determined by microscopy.
•3.Severe malnutrition defined by a very low weight for age (below -3z scores of the median WHO growth standards), by visible severe wasting, or by the presence of nutritional oedema.
•4.Other identifiable cause for the fever (e.g. measles, acute respiratory tract infection)
•5.Long term regular medication, which may interfere with antimalarial pharmacokinetics; such as for TB, HIV, cardiac disease.
•6.History of hypersensitivity or contraindications to any component of the medicine being tested.

发起方

Medical Research Council Unit